Login / Signup

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.

Jeffrey S WeberMichele Del VecchioMario MandalaHelen J GogasAna M AranceStephane DalleC Lance CoweyMichael SchenkerJean-Jacques GrobVanna Chiarion SileniIvan Marquez-RodasMarcus O ButlerAnna Maria Di GiacomoLuis de la Cruz MerinoPetr ArenbergerVictoria AtkinsonAndrew HillLeslie A FecherMichael MillwardNikhil I KhushalaniPaola QueiroloGeorgina V LongMaurice LoboMargarita AskelsonPaolo Antonio AsciertoJames M G Larkin
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Postrecurrence survival was longer for patients who recurred >12 months. Patients on nivolumab who recurred early benefitted from SST but had better survival with ipilimumab-based regimens or targeted therapy compared with anti-PD-1 monotherapy.
Keyphrases